Analysis of the development of the global and Chinese fine chemical industry from 2023 to 2028

Fine chemical industry refers to the industry that produces fine chemicals, commonly known as the fine chemical industry.Products in this industry refer to chemical products with specific application functions, technology-intensive, strong commercial nature, and high product added value.

The market size and future development trend of China's pharmaceutical intermediate industry

China's pharmaceutical intermediate industry is an important part of China's pharmaceutical industry and an important force in promoting the development of China's pharmaceutical industry.In recent years, with the development of China's pharmaceutical industry, China's pharmaceutical intermediate industry has also made great strides.

Analysis of the development of the global and Chinese API industry from 2023 to 2028

API refers to raw materials that meet the requirements of relevant laws and regulations on drug administration and are used in the production of various types of drugs. They are the active ingredients in drugs.Perfect definition in ICH Q7A: Any substance or mixture of substances intended to be used in the manufacture of medicines, and when used in pharmaceuticals, it becomes an active ingredient of medicines.Such substances have pharmacological activity or other direct effects in the diagnosis, treatment, symptom relief, treatment or prevention of diseases, or can affect the function or structure of the body.

Expert interpretation: Judge the clinical selection of tiotropium bromide from three angles!

At present, the prevention and treatment situation of chronic obstructive pulmonary disease in the world is serious.As the current first-line drug for the treatment of chronic obstructive pulmonary disease, tiotropium bromide, the quality of its inhalant products has an important impact on the clinical efficacy and safety. Recently, the "Quality Evaluation of Tiotropium Bromide Inhalation Powder Mist from Different Manufacturers-Experimental Research Report" (hereinafter referred to as the "Report") carried out by Professor Sha Xianyi of the School of Pharmacy of Fudan University and others was published.The study compared the relevant substances and indicators of the characteristics of the inhalation powder mist of tiotropium bromide produced by different domestic and original research manufacturers, and aims to provide a reference and basis for clinical medication.

Scientists confirmed that tiotropium bromide treats patients with early chronic obstructive pulmonary disease

Recently, a large-scale clinical study on the treatment of early chronic obstructive Pulmonary Disease (Tie-COPD) led by the Guangzhou Institute of Respiratory Diseases, the National Clinical Research Center for Respiratory Diseases, and the State Key Laboratory of Respiratory Diseases of the Affiliated Hospital of Guangzhou Medical University (led by the Guangzhou Institute of Respiratory Diseases, the National Clinical Research Center for Respiratory Diseases, and the State Key Laboratory of Respiratory Diseases, with the participation of a number of domestic hospitals, has made breakthroughs in the treatment of early chronic obstructive pulmonary disease (Tie-COPD), confirming that the use of tiotropium bromide to treat patients with early chronic obstructive pulmonary disease is safe and effective.The results of the study were published in the New England Journal of Medicine. Chronic obstructive pulmonary disease is currently one of the diseases with high morbidity and mortality rates in the world.In China, chronic obstructive pulmonary disease has become one of the three deadly health killers, and the prevalence of chronic obstructive pulmonary disease in people over the age of 40 in our country reaches 8.2%.In earlier studies, the team found that more than 70% of patients with chronic obstructive pulmonary disease were early-stage patients, but most of them did not actively seek medical help because they were asymptomatic or had mild symptoms. In the late stage, the treatment effect was poor, and the mortality rate, readmission rate and disability rate were all very high.At the same time, patients with chronic obstructive pulmonary disease have a more rapid decline in early lung function.Therefore, it is very important to find an effective way to intervene in patients with early chronic obstructive pulmonary disease.

With SPS as the core, build standards and norms suitable for China's IT service operations

Technological innovation is the key to core competitiveness.China Digital has built a strong information technology R&D and operation team, with nearly 2,000 software R&D personnel. It is the chairman unit of the “Changfeng Alliance Internet Information Service Industry Promotion Working Group” of the Ministry of Science and Technology. In the true sense, it has proposed a SaaS service system with Chinese characteristics, with SPS as the core to build standards and norms suitable for China's IT service operations.In terms of ICT infrastructure construction, China Digital has established professional data centers in Beijing, Guangzhou, Suzhou and other places to realize the interconnection of north-south telecommunications, build a high-security and highly reliable network environment, and have more than 3,000 operating equipment; through the establishment of joint laboratories with NetApp, HP and other companies, computing pooling and storage pooling have been realized; in the field of e-commerce, it has pioneering the development of e-commerce platforms for on-demand services and personalized services.Now it has applied for more than a dozen technical patents and has become a pilot enterprise of Beijing Patent Engine.